Arcadia Biosciences, Inc., an agricultural technology company focused on developing technologies and products that benefit the environment and human health, announced today that it has successfully completed the first commercial production of SONOVA™ 400 High GLA Safflower Oil. Seed produced by the first High GLA Safflower crop, grown during 2009, was processed to produce commercial quantities of SONOVA™ 400 oil, which is now available for distribution as a key ingredient in dietary supplements...

Functional Technologies Corp. (TSX VENTURE:FEB), a world leader in yeast research and development, announced today that it has developed, tested and filed patent applications for yeast technology that reduces the formation of acrylamide, a carcinogen formed when starchy foods are baked, fried or toasted. Recognized globally as a serious food safety issue since 2002, acrylamide has been found in many widely consumed foods, including bread, cookies, crackers, baby food, breakfast cereal, French fries and potato chips...

AngioScore, Inc., a developer of novel angioplasty catheters for use in the treatment of cardiovascular disease, announced today favorable clinical trial results from the MASCOT Trial, an important study evaluating the AngioSculpt® PTA Scoring Balloon Catheter for the treatment of femoro-popliteal PAD (peripheral artery disease). "PAD is one of the fastest-growing segments of the Endovascular Market, with an estimated two million annual procedures worldwide...

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that GlaxoSmithKline (NYSE: GSK) was granted marketing authorization from the European Commission (EC) for Revolade® (eltrombopag) for the oral treatment of thrombocytopenia (reduced platelet count) in adults with the blood disorder chronic immune (idiopathic) thrombocytopenic purpura (ITP). Eltrombopag is indicated for adult chronic ITP splenectomized patients who have not responded (are refractory) to other treatments, such as corticosteroids and immunoglobulins...

Despite the advances and groundbreaking research being performed in the area of cancer treatment, sometimes cancer cannot be cured. In this situation, patients and their families are faced with complex emotions and a variety of end of life issues and decisions. ABC News veteran and anchor Sam Donaldson shared his own perspective as a cancer survivor while moderating a roundtable of notable panelists at the NCCN 15th Annual Conference: Clinical Practice Guidelines & Quality Cancer Care™ on March 11, 2010. "I had to figure out who I was going to be on my own." Mr...

Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced that it plans to advance oral methylnaltrexone for the treatment of opioid-induced constipation (OIC) into late stage clinical development and will commence a phase 2b/3 clinical trial of a methylnaltrexone tablet in chronic-pain patients in the second half of 2010. Progenics also announced data from a clinical trial of this methylnaltrexone tablet. The tablet form of oral methylnaltrexone was developed by Progenics' former collaboration partner Wyeth...

A new addition to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™), the NCCN Guidelines for Malignant Pleural Mesothelioma (MPM), was presented at the NCCN 15th Annual Conference. Lee M. Krug, MD of Memorial Sloan-Kettering Cancer Center and a member of the NCCN Guidelines Panel discussed recommended treatment options for patients with MPM as well as first-line therapy regimens. Mesothelioma is a rare form of cancer in which malignant cells are found in the mesothelium, a protective sac that covers most of the body's internal organs...

The escalating costs of cancer care combined with variations in concordance with evidence-based practice guidelines is putting the United States on a collision course for an impending collapse of its current health care system according to roundtable panelists at the NCCN 15th Annual Conference. Clifford Goodman, PhD, of The Lewin Group, led an engaging roundtable debating the utilization of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) and the impact of escalating health care costs. Dr...

Orthopaedic surgeon Kevin P. Black, MD, of Hershey, Penn., was elected to the Board of Directors of the American Academy of Orthopaedic Surgeons (AAOS) at the organization's 2010 Annual Meeting in New Orleans. "It's an enormous honor to be elected to the AAOS Board of Directors," said Dr. Black. "I'm looking forward to working with and learning from the other members of the Board and having the opportunity to contribute to our great profession and ultimately the patients for whom we care." Dr...

Using risk stratification to assist in treatment selection was just one of the focal points at a recent presentation of the NCCN Clinical Practice Guidelines for Oncology (NCCN Guidelines™) for Acute Myeloid Leukemia (AML) at the NCCN 15th Annual Conference. B. Douglas Smith, MD of The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and a member of the NCCN Guidelines Panel for AML, spoke about the challenges in treating AML as well as recent updates to the NCCN Guidelines™. Dr...

The National Minority Quality Forum (The Forum) is launching a new public information campaign aimed to help educate consumers, physicians, and policymakers about the risks associated with prescribing and taking unapproved drugs that have not been subjected to the rigorous Food and Drug Administration's (FDA) review and approval process. Unapproved drugs can be dangerous - or even deadly - to patients as a result of the lack of testing, unknown or unregulated ingredients, improper labeling, and as a result of this lack of information, the inability to predict drug to drug interactions...

Bio-Path Holdings, Inc. (OTCBB: BPTH), a publicly traded biotechnology company with drug development operations in Houston, Texas, announced that the U.S. Food and Drug Administration (FDA) has allowed an IND (Investigational New Drug) for the Company's lead cancer drug candidate liposomal Grb-2 to proceed into clinical trials...

Based on its recent analysis of the cardiac molecular imaging systems market, Frost & Sullivan recognizes Positron Corporation with the 2010 North American Award for New Product Innovation, for its pioneering cardiac positron emission tomography (PET) scanner, Attrius™. The Attrius™ was developed and optimized for molecular imaging of the heart, making it the ideal solution for cardiologists and hospitals looking to add high accuracy, cost effective imaging technology...

GE Healthcare' announced that the company's portable ECG (electrocardiograph) device, the MAC 800, will be implemented in both Vancouver and Whistler to help support physician care of athletes, trainers and visitors throughout the Vancouver 2010 Paralymipc Winter Games...

Orthopaedic surgeon Daniel W. White, MD, LTC, MC, was elected to the Board of Directors of the American Academy of Orthopaedic Surgeons (AAOS) at its 2010 Annual Meeting in New Orleans. "As a military physician, I hope to bring a unique perspective to the leadership," said Dr. White. "I am humbled and honored to be a member of the AAOS Board of Directors." Dr. White currently serves as the chief of orthopaedic surgery and rehabilitation services at Evans Army Community Hospital in Fort Carson, Colo...

The U.S. Food and Drug Administration (FDA) issued a drug safety communication to patients and healthcare professionals regarding the use of clopidogrel, an anti-clotting medication. The FDA is requiring a "Boxed Warning" on the label of clopidogrel to tell patients and healthcare providers that certain patients may lack genetic factors required to effectively metabolize the drug. These "poor metabolizers" may not receive the full benefits of clopidogrel. According to the FDA, approximately 2 to 14 percent of the population are poor metabolizers of clopidogrel...

The U.S. Food and Drug Administration (FDA) Neurological Devices Panel today voted seven to five to recommend approval with conditions of Deep Brain Stimulation (DBS) Therapy for Epilepsy from Medtronic, Inc. (NYSE: MDT) as adjunctive treatment for partial-onset seizures in adults with medically refractory epilepsy. If the FDA follows the recommendation of the panel, the therapy will be approved for the treatment of epilepsy in patients who have continued seizures with inadequate response to currently available epilepsy treatments...

Janssen-Cilag announced that PRILIGY® (dapoxetine) is now approved and available for use in New Zealand for the treatment of premature ejaculation (PE) in men 18-64 years of age. PE is a common men's medical condition, but it is rarely talked about. However, it is widespread and could affect the quality of life of an estimated 250,000 New Zealand men and their partners . Dr...

The study, Rising to the challenge: health priorities for the Government and the NHS looks at the scale of the task facing a new administration after this year's General Election. It argues that the demands of a spending squeeze combined with lifestyle factors, the UK's aging population and the increasing cost of healthcare mean the NHS is facing one of the most difficult moments in its history...

Results were presented today on behalf of the National Heart, Lung and Blood Institute from ACCORD, a study in patients with diabetes that evaluated cardiovascular outcomes in three distinct studies - glycemic control, blood pressure control and lipid control. In response to data from the ACCORD Lipid study, Abbott issued the following statement: "The results of ACCORD Lipid were widely expected and not surprising given that two-thirds of patients in the trial would not be treated with fibrates under current guidelines," said Eugene Sun, M.D...